<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Seres Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/seres-therapeutics-inc</link>
<description>Latest news and press releases for Seres Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/seres-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683596a078dffbe2df104a5e.webp</url>
<title>Seres Therapeutics Inc</title>
<link>https://6ix.com/company/seres-therapeutics-inc</link>
</image>
<item>
<title>Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in shaping outcomes in IBD and immunocompromised patients CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced three presentations at the 2026 European Society of Cl</description>
</item>
<item>
<title>Seres Therapeutics to Present at CARB-X Investor Day</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-to-present-at-carb-x-investor-day</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-to-present-at-carb-x-investor-day</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerat</description>
</item>
<item>
<title>Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-5</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with</description>
</item>
<item>
<title>Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-appointment-of-richard-n-kender-as-executive-chair-and-interim-ceo-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-appointment-of-richard-n-kender-as-executive-chair-and-interim-ceo-provides-business-updates</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients</description>
</item>
<item>
<title>Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-provides-program-corporate-updates-120000256</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-provides-program-corporate-updates-120000256</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company’s runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early</description>
</item>
<item>
<title>Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-publications-nature-120000069</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-publications-nature-120000069</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high...</description>
</item>
<item>
<title>Seres Therapeutics to Participate in Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-participate-piper-sandler-120000953</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-participate-piper-sandler-120000953</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at http://www.serestherapeutics.com and will be availab</description>
</item>
<item>
<title>Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-third-quarter-120000372</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-third-quarter-120000372</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoin</description>
</item>
<item>
<title>Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-third-quarter-110000545</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-third-quarter-110000545</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 8471287. To join the live webcas</description>
</item>
<item>
<title>Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-receives-award-3-110000920</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-receives-award-3-110000920</guid>
<pubDate>Wed, 29 Oct 2025 11:00:00 GMT</pubDate>
<description>Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infectionsCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug</description>
</item>
<item>
<title>Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-present-post-hoc-110000530</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-present-post-hoc-110000530</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19–22 in Atlanta, Georgia. Presentation DetailsAbstract ID: 2106936Title: Clinical and Microbiology Outcomes of Bloodstream Infections (BSI) in Adults Undergoing Allogeneic Hematopoietic Stem Ce</description>
</item>
<item>
<title>Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-further-constructive-110000366</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-further-constructive-110000366</guid>
<pubDate>Tue, 23 Sep 2025 11:00:00 GMT</pubDate>
<description>Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Company continues to engage in discussions aimed at obtaining capital and other resources to advance the SER-155 Phase 2 study and is preparing to rapidly operationalize the study, pending securing capital, with interim clinical results</description>
</item>
<item>
<title>Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-participate-h-c-110000249</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-participate-h-c-110000249</guid>
<pubDate>Wed, 27 Aug 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres Therapeu</description>
</item>
<item>
<title>Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-second-quarter-110000496</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-second-quarter-110000496</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherape</description>
</item>
<item>
<title>Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-second-quarter-110100233</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-second-quarter-110100233</guid>
<pubDate>Tue, 22 Jul 2025 11:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast</description>
</item>
<item>
<title>Seres Therapeutics Announces Leadership Transition</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-leadership-transition-110000175</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announces-leadership-transition-110000175</guid>
<pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
<description>Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NE</description>
</item>
<item>
<title>Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-presents-expanded-ser-110000393</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-presents-expanded-ser-110000393</guid>
<pubDate>Tue, 27 May 2025 11:00:00 GMT</pubDate>
<description>Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 A</description>
</item>
<item>
<title>Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-first-quarter-110000339</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-reports-first-quarter-110000339</guid>
<pubDate>Wed, 07 May 2025 11:00:00 GMT</pubDate>
<description>In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% r</description>
</item>
<item>
<title>Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-presents-data-2025-110000306</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-presents-data-2025-110000306</guid>
<pubDate>Tue, 29 Apr 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intes</description>
</item>
<item>
<title>Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025</title>
<link>https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-first-quarter-110000904</link>
<guid isPermaLink="true">https://6ix.com/company/seres-therapeutics-inc/news/seres-therapeutics-announce-first-quarter-110000904</guid>
<pubDate>Wed, 23 Apr 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, p</description>
</item>
</channel>
</rss>